

(51) International Patent Classification ⁵ : A61K 37/36		A1	(11) International Publication Number: WO 91/03253
			(43) International Publication Date: 21 March 1991 (21.03.91)
(21) International Application Number: PCT/GB90/01399 (22) International Filing Date: 10 September 1990 (10.09.90) (30) Priority data: 8920381.4 8 September 1989 (08.09.89) GB (71) Applicant (for all designated States except US): GREATER GLASGOW HEALTH BOARD [GB/GB]; 112 Ingram Street, Glasgow (GB). (72) Inventor; and (75) Inventor/Applicant (for. US only): McCUIISH, Angus, Carstairs [GB/GB]; Glasgow Royal Infirmary, Castle Street, Glasgow G4 0SF (GB). (74) Agent: CRUIKSHANK & FAIRWEATHER; 19 Royal Exchange Square, Glasgow G1 3AE (GB).		(81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent)*, DK (European patent), ES (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent), US. Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: TREATMENT OF INSULIN-RESISTANT DIABETES			
(57) Abstract			
Insulin-like growth factor (IGF) is used for treatment of type A insulin-resistant diabetes by reduction of glucose levels. The treatment is applicable to Mendenhall's Syndrome, Werner Syndrome, leprechaunism, lipotrophic diabetes, and other lipotrophies.			
BEST AVAILABLE COPY			

DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Monaco
AU	Australia	FI	Finland	MG	Madagascar
BB	Barbados	FR	France	ML	Mali
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GR	Greece	NL	Netherlands
BJ	Benin	HU	Hungary	NO	Norway
BR	Brazil	IT	Italy	PL	Poland
CA	Canada	JP	Japan	RO	Romania
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
DE	Germany	LU	Luxembourg	TD	Chad
DK	Denmark			TG	Togo
				US	United States of America

TREATMENT OF INSULIN-RESISTANT DIABETESTechnical Field

The present invention relates to the treatment of insulin-resistant diabetes. In this rare condition, hyperglycaemia (elevated blood glucose) does not respond to administered insulin, possibly due to a genetic abnormality in the cellular insulin receptor which prevents insulin from performing its normal role.

Background

The syndrome which bears his name was first described by Mendenhall in 1950 in three children from one family. All developed insulin-resistant diabetes when aged about 7 years and subsequently died in ketoacidotic coma. Several constant somatic abnormalities were noted, including early dentition, facial dysmorphism and tonsillar hypertrophy which predisposed to the development of middle ear sepsis. The children had enlarged external genitalia with abdominal protuberance and in common with other insulin-resistant states, acanthosis nigricans was observed. Pineal hyperplasia was found at post-mortem, the cause remaining obscure.

In 1975 the syndrome was described in two siblings from a family in the UK. One died at the age of 7 years, in the other, emergency hypophysectomy was performed and proved to be life-saving when the child developed

ketoacidotic coma. The cause of insulin-resistant diabetes in this distressing syndrome was subsequently examined by Taylor et al in a further patient and marked decrease in the cellular binding of insulin was demonstrated by in-vitro culture of cell lines from the child. Thus Mendenhall's syndrome is regarded as analogous to other rare forms of diabetes with acanthosis nigricans, i.e. type A insulin resistance, where functional/structural impairment of the insulin receptor B submit results from an abnormality of the insulin receptor gene.

Further examples of type A insulin resistance would be Werner Syndrome in women, lepreornism, lipoatrophic diabetes and other lipoatrophies.

In the light of those observations, it is not surprising that conventional antidiabetic therapies (dietary manipulation, oral hypoglycaemics, insulin injections) have been entirely ineffective in the Mendenhall syndrome. Young patients with the Mendenhall and similar rare syndromes are at high risk of death from ketoacidotic coma if their state of chronic and gross hyperglycaemia is further adversely affected by physiological events (e.g. puberty, menstruation) or added pathology (e.g. infection).

IGF-1 has structural similarities to proinsulin. However, its cell receptor is different to that of insulin. IGF has been investigated for its potential

growth-enhancing effects on farmed animals . It has also been administered to patients having Laron - type dwarfism (Laron Z. et al. Lancet 1988; 2; 1170-2).

A process for the production of IGF-1, involving synthesis through the use of recombinant DNA technology, is described in EP-A-0219814. The resulting recombinant IGF-1 is identical in terms of its amino acid composition to naturally occurring human IGF-1.

EP-A-0308386 describes a method for improving the regeneration of transected peripheral nerves in mammals and man, for instance following damage by an accident or surgery, which comprises administering IGF-1.

JP-A-63/196524 relates to a permucosal absorptive carcinostatic action regulator comprising (a) a growth factor, such as IGF-1, and (b) an absorption accelerator.

EP-A-0289584 discloses a wound healing and bone regenerating composition which comprises a mixture of purified platelet-derived growth factor and purified IGF-1. The composition may be used in the healing of external wounds in mammals and is said to act by promoting growth of epithelial and connective tissues and the synthesis of total protein and collagen. EP-A-0237514 describes enhancing the growth of mammary parenchyma in mammals by the intra-mammary administration of a mitogenic agent, such as IGF-1.

EP-A-0209331 relates to the extraction of pure bovine IFG-1 and its use as an animal growth promoter.

FR-A-2533438 refers to the use in cosmetic preparations of various growth factors, such as IGF-1, which have been shown to have a mitogenic action on human or animal skin cells. EP-A-0104933 describes a method for growth promotion and feed efficiency improvement which involves the continuous intravenous or subcutaneous administration of IGF-1.

Summary of the Invention

It is an object of the present invention to provide a treatment for insulin-resistant diabetes.

The present invention relates to the therapeutic use of insulin-like growth factor (IGF) for the treatment of type-A insulin-resistant diabetes.

The invention also provides a method of treatment of a patient having type-A insulin-resistant diabetes which comprises the administration of a therapeutically effective amount of insulin-like growth factor.

The invention further provides the use of insulin-like growth factor for the manufacture of a medicament for the treatment of type-A insulin-resistant diabetes.

Insulin-like growth factors are known and occur naturally in the body. Whilst the present invention is primarily concerned with IGF-1, IGF-2 (which is about ten times more potent) may also be employed. The IGF may be made using recombinant DNA techniques in view of its more ready availability. The IGF protein structure may be

identical to the native product or differ from it by additions, deletions or replacements which leave unaffected its cell receptor binding properties and glucose-reducing effect.

The IGF is usually administered intravenously, subcutaneously or intramuscularly in a dosage such as to provide a target blood plasma level of 50 - 150 micrograms per kg. This intravenous injection is usually at a nominal dosage rate of 3-6 mg/kg body weight. By analogy to known dose-response relationships for insulin, corresponding dosages for subcutaneous and intramuscular administration can be derived. Since IGF has a short halflife in-vivo, administration by intravenous injection may need to be repeated several times a day. Subcutaneous injection has a more extended duration and may be administered less frequently e.g. twice daily.

The IGF may be formulated for extended release by combination with suitable agents (haptens, zinc etc) conventionally used for insulin.

Referred Embodiment

An embodiment of the present invention will now be described by way of example only.

CASE REPORT

The patient was the second child of healthy non-consanguineous parents and was born at 44 weeks'

gestation after an uneventful pregnancy. He weighed 2.5kg. at birth and was noted to have abdominal distension, an enlarged phallus and facial dysmorphism. Diabetes mellitus was diagnosed at age 7 years and initial treatment, by dietary/carbohydrate restriction, was unsuccessful. Subsequent therapeutic trials of an oral sulphonylurea (Tolbutamide) and a biguanide (Metformin) were equally ineffective. The injection of subcutaneous insulin (up to 100 units per day) had no appreciable effect on either mean daily blood glucose or glycated haemoglobin level (14.2%, laboratory normal 8%).

By the age of 13 years, he had an established metabolic pattern of gross, chronic hyperglycaemia and intermittent ketonuria. The patient's endogenous levels of IGF-1 were subnormal for his age.

METHODS

Plasma insulin and C-peptide were measured using standard radio-immunoassay (RIA) procedures described previously (1). Plasma IGF-1 was measured using the RIA kit supplied by Nichols Institute Diagnostics, San Juan, California; serum growth hormone was determined using an in-house immunoradiometric assay standardised against the First International Reference Preparation of human growth hormone (MRC 66/217; 2 μ u = 1 μ g). Insulin binding status was assessed by platelet binding techniques (2,3). IGF-1 was donated by the Fujisawa Pharmaceutical Company,

synthesised by recombinant DNA technology and had an aminoacid sequence identical to that of native human IGF-1 (4). Lyophilised IGF-1 was dissolved in normal saline and injected as a single intravenous bolus of 3 mgm (100 ug/kg) after breakfast. Venous blood was withdrawn for analysis through an indwelling catheter at 0, 2, 5, 15, 30, 60, 120, and 180 minutes after injection. further boluses of 6 and 12 mgm respectively were subsequently given in the fasted state with hormonal profiles measured after the latter dose. A further experiment was performed with a 12 mgm intravenous bolus of IGF-1 given before breakfast and followed by hourly hormonal sampling until 5 p.m. For purposes of comparison, the hormonal response to standard meals was measured and a 75 G oral glucose tolerance test was performed after an overnight fast.

RESULTS

Initial IGF-1 level prior to therapy was subnormal at 0.2 ku/l (normal 0.5 to 4.0 ku/l, corrected for sex and age). Insulin binding status was examined and found to be impaired (Table 1). Oral glucose tolerance testing (75 G load) confirmed marked hyperglycaemia with gross hyperinsulinaemia (Table 2). Following a 3 mgm intravenous bolus of IGF-1, given post prandially, blood glucose fell to a nadir of 11.2 mmols/l after 120 minutes (Figure 1). Plasma insulin declined rapidly from 1290 to 315 mu/l (Figure 3); C-peptide from 1.92 to 0.88 nmols/l

and HGH from 11.2 to 0.5 $\mu\text{u}/\text{l}$ (Figure 2). Also given for comparison is the response to a placebo (intravenous isotonic saline bolus) in insulin, C-peptide, HGH and blood glucose following a standard hospital breakfast (carbohydrate content 50 G). Similar findings were observed following a 6 mgm intravenous bolus; and after a 12 mgm bolus, given in the fasting state, blood glucose declined to 8.3 mmols/l . Thereafter boluses of 12mgm IGF-1 were given intravenously before breakfast and lunch: mean blood glucose over an 8-hour period was 17.4 mmols/l and mean plasma insulin 290.2 $\mu\text{u}/\text{l}$. By comparison, a mean blood glucose of 29.1 mmols/l and mean plasma insulin of 769 $\mu\text{u}/\text{l}$ was observed over the same time period when no therapy was given.

REFERENCES

1. Small M, Cohen HN, Beastall GH, MacCuish AC.
Comparison of oral glucose loading and intravenous glucagon injection as stimuli to C-peptide secretion in normal men. Diabetic Med 1985; 2: 181-3
2. Hajek AS, Joist JH, Baker RK et al. Demonstration and partial characterisation of insulin receptors in human platelets. J. Clin Invest 1979; 63: 1060-5

3. Udvardy M, pfiegler G, Rak K. Platelet insulin receptor determination in non-insulin dependent diabetes mellitus. *Experientia* 1985; 41: 422-33.

4. Niwa M, Sato S, Saito Y et al. Chemical synthesis, cloning and expression of genes for human somatomedin C (insulin-like growth factor 1) and 59Val-somatomedin C: *Ann NY Acad Sci* 1986; 469: 31-52.

-10-

TABLE 1

Insulin concentration
in supernatant (ng/ml)

Specific insulin binding
(pg.2x10⁸ platelets)

	<u>PATIENT</u>	<u>CONTROLS</u>
0.1	0.27	0.37 ± 0.09
0.2	0.35	0.62 ± 0.17
0.6	1.48	1.70 ± 0.45
1.0	1.48	2.73 ± 0.83

Insulin receptor status (insulin binding) of platelets
from patients and controls determined by in vitro assay.

TABLE 2

<u>Time (min)</u>	<u>Glucose</u>	<u>HGH</u>	<u>Insulin</u>	<u>C-peptide</u>
0	11.7	0.9	407	2.3
30	18.9	0.6	510	5.5
60	30.1	0.5	1600	10.2
90	29.9	0.7	934	4.1
120	24.4	6.9	726	3.9

Blood glucose and hormone levels after oral glucose
loading (75g), following an overnight fast. Glucose in
mmol/l; HGH and insulin in mU/l; C-peptide in nmol/l.




SUBSTITUTE SHEET

CLAIMS

1. The therapeutic use of insulin-like growth factor (IGF) for the treatment of insulin-resistant diabetes.
2. A method of treatment of a patient having insulin-resistant diabetes which comprises the administration of a therapeutically effective amount of insulin-like growth factor (IGF).
3. A method/use according to claim 1 or 2 for the treatment of type A insulin resistant diabetes.
4. A method/use according to claim 1 or 2 for the treatment of mendenhall's syndrome.
5. A method/use according to claim 1 or 2 for the treatment of Werner Syndrome, lepreornism, Lipoatrophic diabetes and other lipoatrophies.
6. A method/use according to claim 1 or 2 which employs IGF-1.
7. A method/use according to claim 1 or 2 which comprises administration of IGF such as to provide a target blood plasma level of 50-150 micrograms per kg.




8. A method/use according to claim 1 or 2 which comprises administration of IGF at a dosage rate of 3-6 mg per kg body weight.
9. The use of insulin-like growth factor (IGF) for the manufacture of a medicament for the treatment of insulin-resistant diabetes.
10. A sustained release pharmaceutical formulation which comprises insulin-like growth factor (IGF) together with suitable sustained release formulation adjuncts.

—●— Response to placebo after meal
- -○- - Response to 3mg IV HGH after meal



INTERNATIONAL SEARCH REPORT

International Application No **PCT/GB 90/01399**

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC IPC ⁵ : A 61 K 37/36														
II. FIELDS SEARCHED <div style="text-align: right; font-size: small;">Minimum Documentation Searched ⁷</div> <table style="width: 100%; border: none;"> <tr> <td style="width: 30%; border: none;">Classification System</td> <td style="border: none;">Classification Symbols</td> </tr> <tr> <td style="border: none; vertical-align: top;">IPC⁵</td> <td style="border: none; vertical-align: top;">A 61 K, C 07 K</td> </tr> </table> <div style="text-align: center; font-size: x-small; margin-top: 5px;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸</div>			Classification System	Classification Symbols	IPC ⁵	A 61 K, C 07 K								
Classification System	Classification Symbols													
IPC ⁵	A 61 K, C 07 K													
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹ <table border="1" style="width: 100%; border-collapse: collapse; font-size: small;"> <thead> <tr> <th style="width: 10%;">Category ¹⁰</th> <th style="width: 70%;">Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²</th> <th style="width: 20%;">Relevant to Claim No. ¹³</th> </tr> </thead> <tbody> <tr> <td style="text-align: center; vertical-align: top;">X</td> <td>EP, A, 0331630 (CIBA-GEIGY) 6 September 1989 see the whole document ---</td> <td style="text-align: center; vertical-align: top;">9-10</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">X,P</td> <td>EP, A, 0360411 (KABIVITRUM AB) 28 March 1990 see the whole document, especially columns 6-8 "Biological activity" ---</td> <td style="text-align: center; vertical-align: top;">9-10</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">Y</td> <td>The New England Journal of Medicine, volume 317, no. 3, 16 July 1987, H.P. Guler et al.: " Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults", pages 137-140 see the whole article --- ./.</td> <td style="text-align: center; vertical-align: top;">9-10</td> </tr> </tbody> </table>			Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	X	EP, A, 0331630 (CIBA-GEIGY) 6 September 1989 see the whole document ---	9-10	X,P	EP, A, 0360411 (KABIVITRUM AB) 28 March 1990 see the whole document, especially columns 6-8 "Biological activity" ---	9-10	Y	The New England Journal of Medicine, volume 317, no. 3, 16 July 1987, H.P. Guler et al.: " Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults", pages 137-140 see the whole article --- ./.	9-10
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³												
X	EP, A, 0331630 (CIBA-GEIGY) 6 September 1989 see the whole document ---	9-10												
X,P	EP, A, 0360411 (KABIVITRUM AB) 28 March 1990 see the whole document, especially columns 6-8 "Biological activity" ---	9-10												
Y	The New England Journal of Medicine, volume 317, no. 3, 16 July 1987, H.P. Guler et al.: " Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults", pages 137-140 see the whole article --- ./.	9-10												
<div style="display: flex; justify-content: space-between; font-size: x-small;"> <div style="width: 45%;"> <p>* Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p> </div> </div>														
IV. CERTIFICATION <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; padding: 5px;"> Date of the Actual Completion of the International Search <div style="text-align: center;">7th December 1990</div> </td> <td style="width: 50%; padding: 5px;"> Date of Mailing of this International Search Report <div style="text-align: center;">31.12.91</div> </td> </tr> <tr> <td style="width: 50%; padding: 5px;"> International Searching Authority <div style="text-align: center;">EUROPEAN PATENT OFFICE</div> </td> <td style="width: 50%; padding: 5px;"> Signature of Authorized Officer <div style="text-align: center;">  MARIA TORIBIO </div> </td> </tr> </table>			Date of the Actual Completion of the International Search <div style="text-align: center;">7th December 1990</div>	Date of Mailing of this International Search Report <div style="text-align: center;">31.12.91</div>	International Searching Authority <div style="text-align: center;">EUROPEAN PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center;">  MARIA TORIBIO </div>								
Date of the Actual Completion of the International Search <div style="text-align: center;">7th December 1990</div>	Date of Mailing of this International Search Report <div style="text-align: center;">31.12.91</div>													
International Searching Authority <div style="text-align: center;">EUROPEAN PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center;">  MARIA TORIBIO </div>													

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

Y

Diabetologia, volume 31, 1988, Diabetologia
 Springer-Verlag, Pub.,
 N. Livingston et al.: "Characterisation
 of insulin-like growth factor I receptor
 in skeletal muscles of normal and
 insulin resistant subjects", pages
 871-877
 see the whole article

9-10

V. ☒ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE ¹

This International search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☒ Claim numbers because they relate to subject matter not required to be searched by this Authority, namely:

*- claims 1-8
 see PCT- Rule 39.1(IV) methods for treatment of the human
 or animal body by surgery or therapy, as well as diagnos-
 tic methods.

2. ☐ Claim numbers because they relate to parts of the international application that do not comply with the prescribed require-
 ments to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claim numbers because they are dependent claims and are not drafted in accordance with the second and third sentences of
 PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ²

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims
 of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only
 those claims of the international application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to
 the invention first mentioned in the claims; it is covered by claim numbers:
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not
 invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

GB 9001399

SA 40121

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 15/01/91
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0331630	06-09-89	AU-A- 2899989	10-08-89
		JP-A- 1233227	19-09-89
EP-A- 0360411	28-03-90	AU-A- 4051889	23-03-90
		WO-A- 9002198	08-03-90

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.